Prognostic importance of immunologochemical markers of papillary thyroid cancer
DOI:
https://doi.org/10.15587/2519-4798.2019.155632Keywords:
papillary thyroid cancer, TTF1, Ki-67, NIS, Gal3, p53, prognosis of outcomeAbstract
In Papillary Thyroid Cancer (PTC) in recent years an immunohistochemical markers were detected. Several authors consider their use as perspective to predict tumor behavior and the risk of recurrence and for differential diagnosis between different variants of PTC. However, the data obtained during various studies are controversial, which necessitates further research.
Materials and methods: Using standard methods, the pathogistological material was obtained after surgical treatment of 273 patients with PTC. Expression of immunohistochemical markers: TTF1 and Gal3 - in 48 patients, p53 - in 50 patients, Ki-67 in 53 patients, NIS in 44 patients detected immunohistochemically. The connection between the histological type of tumor, the level of expression of immunohistochemical markers and the histological signs of aggressive tumor behavior are analyzed: multifocal, capsule invasion, extratireoidal invasion, lymph node damage.
Results: In the analysis of data obtained with the use of standard histological techniques, it was found that the most aggressive variant was cylindrical cells PTC with a high incidence of extrathyroid invasion - 5.4 %, a capsule invasion -7.2 %, multifocal growth - 10.8 %, metastatic lymph nodes – 17.1 %. The high levels of TTF1 and Ki-67 expression, as well as the absence of NIS expression, were reliably associated with metastatic lymph node involvement (p <0.05). Reliable relationship with other histological signs of aggressive behavior of the tumor was not detected. No association was found between Gal3 and p53 expression levels and signs of aggressive tumor behavior. The data obtained in the study suggest that immunohistochemical markers reflect the processes characterizing the biological pathomorphism of the tumor and indicate a gradual loss of differentiation signs in more aggressive tumors.
Conclusions: immunohistochemical markers changes reflect biological pathomorphism of the tumor, overexpression of ki67 and TTF1, as well as the loss of NIS, suggest a greater malignant tumor potential. The obtained data may help in individualized choice of surgical procedure
References
- Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E. et. al. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26 (1), 1–133. doi: http://doi.org/10.1089/thy.2015.0020
- Miccoli, P., Materazzi, G., Macerola, E., Bakkar, S. (2018). Tailored surgery according to molecular analysis in differentiated thyroid carcinomas. Gland Surgery, 7 (S1), S30–S33. doi: http://doi.org/10.21037/gs.2017.10.07
- Karachentsev, Yu. I., Dubovik, V. M., Goydenko, N. I. et. al. (2014). Viznachennya gistologіchnyh forms of papіlyarnogo cancer of thyroid-podschiko zalozy zvikristannyam іm immunogistokhіmichnyh markers [Determination of histological forms of papillary thyroid cancer using immunohistochemical markers]. Endocrinologya, 19 (4), 302.
- Semyonov, D. U., Boriskova, M. E., Farafonova, U. V., Grozov, R. V., Pankova, P. A., Smolina, E. N. (2015). Prognosticheskoye znacheniye ekspressii natriy-yodnogo simportera dlya vysokodifferentsirovannogo raka shchitovidnoy zhelezy [Prognostic value of Sodium-Iodide Symporter (NIS) in differentiated thyroid cancer]. Klinicheskaya i eksperimental'naya tireoidologiya, 11 (1), 50–58.
- Dwivedi, S. S., Khandeparkar, S. G., Joshi, A. R., Kulkarni, M. M., Bhayekar, P., Jadhav, A. et. al. (2016). Study of Immunohistochemical Markers (CK-19, CD-56, Ki-67, p53) in Differentiating Benign and Malignant Solitary Thyroid Nodules with special Reference to Papillary Thyroid Carcinomas. Journal of Clinical and Diagnostic Research, 10 (12), EC14-EC19. doi: http://doi.org/10.7860/jcdr/2016/22428.9114
- Gerval’d, V. Y., Klimachev, V. V., Avdalian, A. M., Ivanov, A. A., Bobrov, I. P., Lepilov, A. V. et. al. (2014). Rak shchitovidnoy zhelezy i metody yego immunogistokhimicheskoy diagnostiki [The thyroid cancer and its immunohistochemical diagnosis]. Fundamental'nyye issledovaniya, 10, 191–1917.
- Sciacchitano, S., Lavra, L., Ulivieri, A., Magi, F., De Francesco, G. P., Bellotti, C. et. al. (2017). Comparative analysis of diagnostic performance, feasibility and cost of different test-methods for thyroid nodules with indeterminate cytology. Oncotarget, 8 (30), 49421–49442. doi: http://doi.org/10.18632/oncotarget.17220
- Miyauchi, A., Kudo, T., Hirokawa, M., Ito, Y., Kihara, M., Higashiyama, T. et. al. (2013). Ki-67 Labeling Index Is a Predictor of Postoperative Persistent Disease and Cancer Growth and a Prognostic Indicator in Papillary Thyroid Carcinoma. European Thyroid Journal, 2 (1), 57–64. doi: http://doi.org/10.1159/000347148
- Tang, J., Kong, D., Bu, L., Wu, G. (2017). Surgical management for follicular variant of papillary thyroid carcinoma. Oncotarget, 8 (45), 79507–79516. doi: http://doi.org/10.18632/oncotarget.18525
- Dubovik, V. N., Karachentsev, Yu. I., Khaziev, V. V. (2013). Otdalennyye rezul'taty khirurgicheskogo lecheniya papillyarnogo raka shchitovidnoy zhelezy [Long-term results of surgical treatment of papillary thyroid cancer]. Suchasni medichni tekhnologii, 3, 60–62.
- Xing, M., Haugen, B. R., Schlumberger, M. (2013). Progress in molecular-based management of differentiated thyroid cancer. The Lancet, 381 (9871), 1058–1069. doi: http://doi.org/10.1016/s0140-6736(13)60109-9
- Gonçalves, C., de Freitas, M., Ferreira, A. (2017). Flavonoids, Thyroid Iodide Uptake and Thyroid Cancer – A Review. International Journal of Molecular Sciences, 18 (6), 1247. doi: http://doi.org/10.3390/ijms18061247
- Manzella, L., Stella, S., Pennisi, M., Tirrò, E., Massimino, M., Romano, C. et. al. (2017). New Insights in Thyroid Cancer and p53 Family Proteins. International Journal of Molecular Sciences, 18 (6), 1325. doi: http://doi.org/10.3390/ijms18061325
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Yuri Vinnik, Vadim Khaziev, Alika Korkelia, Alexandr Gorbulitch
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
